PIRS

Palvella Therapeutics Inc (PIRS) | Rumor.io

Palvella Therapeutics

PIRS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,804

Bullish sentiment (50-day avg)100%

Price to earnings ratio-6.4

Market capitalization170.9M

Earnings per share-21.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PIRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jul 25

$PIRS is considered a stock on the verge of an explosion, with a potential breakout above $17.50.
The stock has broken resistance and may see a squeeze, with some traders expecting a gap up tomorrow.
With 1.3 million shares outstanding, $PIRS is seen as a potentially explosive stock, with a 52-week high of $41.00+ a possibility.

Generated by AI

Sentiment

Of the messages about PIRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	14.29% -59.08
Bearish	—	—	—	85.71% +59.08

Bullish· Jul 24

$PIRS has shown significant price jumps, including a 72% increase in pre-market trading, indicating strong market interest.
The company's merger announcement and phase 3 trials are expected to drive future growth, with potential for a "future pump" and a "tiny float" that could "fly" when scalping is done.
PIRs' micro float and strong momentum are creating a bullish environment, with moving averages and support levels indicating potential for continued growth, making it a "runner" with potential to reach $20.

Bearish· Jul 24

$PIRS is at high risk of a significant price drop due to its history of scams and failed mergers.
The company's recent merger and $80 financing deal may not be enough to sustain its stock price, which could lead to a sharp decline.
Short covering and high short volume have contributed to the stock's volatility, making it a high-risk investment.

Generated by AI

Topics

Of the messages about PIRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Analysts· Mar 19

Pieris Pharmaceuticals ($PIRS) initiated with an Outperform rating and $13 price target by Evercore ISI.
Jefferies initiates coverage of Pieris Pharmaceuticals ($PIRS) with a Buy rating and $12 price target.
Analysts at Jefferies and Evercore ISI expect Pieris Pharmaceuticals ($PIRS) to see momentum in the second half of 2018 on first-in-human data from its pipeline candidates.

Announcements· Aug 17

Pieris Pharmaceuticals (PIRS) has announced a milestone achievement for Boston Pharmaceuticals' initiation of Phase 1/2 study of BOS-342, a 4-1BB/GPC3 immuno-oncology bispecific.
The company is entitled to receive up to approximately $350 million in development, regulatory, and sales-based milestone payments, and tiered royalties on sales of BOS-342.
Pieris Pharmaceuticals is exploring strategic options, which may include an acquisition, merger, or reverse merger, and has a cash position worth 3 times its current market cap.

Technical Analysis· Jun 25

PIRS has formed a potential ascending triangle with a target of 5.40, following a break above 5.25.
The stock has given a buy signal, with the RSI touching 30 and a possible reversal incoming, as the 200 EMA line comes down and the parabolic SAR signals a bullish trend.
PIRS has entered an uptrend, with the momentum indicator exceeding the 0 level, and has a strong support level at 4.15, which could lead to a reversal if broken.

Generated by AI

Community

Of the messages about PIRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	75%
Newcomers	—	—	—	25%

Regulars· Jun 21

AstraZeneca has discontinued the Phase 2a trial of Pieris Pharmaceuticals' asthma treatment, Elarekibep (PRS-060/AZD1402), due to new non-clinical safety findings from a 13-week toxicology study.
The discontinuation of the trial is a significant setback for Pieris Pharmaceuticals, which may need to reshuffle its partnerships and focus, and potentially even consider selling the company to return value to shareholders.
Pieris Pharmaceuticals' stock price has plummeted by 59.79% in the pre-market, with some investors considering the company "done" and others taking losses on small positions.

Newcomers· Jul 18

Pieris Pharmaceuticals is adjusting its strategy after AstraZeneca's discontinuation of enrollment and termination of their collaboration agreement.
The company is restructuring, reducing its workforce by approximately 70% as part of its cash preservation plan.
Pieris Pharmaceuticals' stock is experiencing a significant increase in price, up 20.25% as of the latest update, amidst the corporate restructuring and potential partnership opportunities.

Generated by AI

Also Discussed

Investors talking about PIRS also mention

#	Name	Attention
1	AFMD - Affimed N.V.	——
2	Fate Therapeutics Inc.FATE	0%new
3	Calithera Biosciences Inc.CALA	0%0
4	BLCM - Bellicum Pharmaceuticals, Inc.	——
5	Immatics N.V.IMTX	0%0
6	MRTX - Mirati Therapeutics, Inc.	——
7	JNCE - Jounce Therapeutics, Inc.	——
8	XOMA CorporationXOMA	0%0
9	MRNS - Marinus Pharmaceuticals, Inc.	——
10	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0

Palvella Therapeutics Inc

Healthcare
Biotechnology

Palvella Therapeutics Inc is a pharmaceutical company committed to the development of therapies for rare and serious dermatologic conditions. Its primary focus lies in creating innovative treatments that address unmet medical needs in the dermatology sector, particularly targeting genetic diseases. Palvella leverages advanced biopharmaceutical techniques to develop topical treatments that aim for both efficacy and patient safety. Among its key projects are therapies for conditions like pachyonychia congenita, a rare disorder affecting nails and skin. The company collaborates with research institutions, leveraging cutting-edge science to turn insights into clinical solutions. Operating within the biopharmaceutical industry, Palvella plays a vital role in pioneering treatments that have the potential to transform patient care. By focusing on niche markets within dermatology, where competitive products are limited, Palvella Therapeutics Inc contributes significantly to the advancement of specialized healthcare solutions.

Website

Location

125 Strafford Avenue

Wayne, PA, 19087

United States

Social

What share of all stock conversation is about PIRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Jul 25

$PIRS is considered a stock on the verge of an explosion, with a potential breakout above $17.50.
The stock has broken resistance and may see a squeeze, with some traders expecting a gap up tomorrow.
With 1.3 million shares outstanding, $PIRS is seen as a potentially explosive stock, with a 52-week high of $41.00+ a possibility.

Generated by AI

Sentiment

Of the messages about PIRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	14.29% -59.08
Bearish	—	—	—	85.71% +59.08

Bullish· Jul 24

$PIRS has shown significant price jumps, including a 72% increase in pre-market trading, indicating strong market interest.
The company's merger announcement and phase 3 trials are expected to drive future growth, with potential for a "future pump" and a "tiny float" that could "fly" when scalping is done.
PIRs' micro float and strong momentum are creating a bullish environment, with moving averages and support levels indicating potential for continued growth, making it a "runner" with potential to reach $20.

Bearish· Jul 24

$PIRS is at high risk of a significant price drop due to its history of scams and failed mergers.
The company's recent merger and $80 financing deal may not be enough to sustain its stock price, which could lead to a sharp decline.
Short covering and high short volume have contributed to the stock's volatility, making it a high-risk investment.

Generated by AI

Topics

Of the messages about PIRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Analysts· Mar 19

Pieris Pharmaceuticals ($PIRS) initiated with an Outperform rating and $13 price target by Evercore ISI.
Jefferies initiates coverage of Pieris Pharmaceuticals ($PIRS) with a Buy rating and $12 price target.
Analysts at Jefferies and Evercore ISI expect Pieris Pharmaceuticals ($PIRS) to see momentum in the second half of 2018 on first-in-human data from its pipeline candidates.

Announcements· Aug 17

Pieris Pharmaceuticals (PIRS) has announced a milestone achievement for Boston Pharmaceuticals' initiation of Phase 1/2 study of BOS-342, a 4-1BB/GPC3 immuno-oncology bispecific.
The company is entitled to receive up to approximately $350 million in development, regulatory, and sales-based milestone payments, and tiered royalties on sales of BOS-342.
Pieris Pharmaceuticals is exploring strategic options, which may include an acquisition, merger, or reverse merger, and has a cash position worth 3 times its current market cap.

Technical Analysis· Jun 25

PIRS has formed a potential ascending triangle with a target of 5.40, following a break above 5.25.
The stock has given a buy signal, with the RSI touching 30 and a possible reversal incoming, as the 200 EMA line comes down and the parabolic SAR signals a bullish trend.
PIRS has entered an uptrend, with the momentum indicator exceeding the 0 level, and has a strong support level at 4.15, which could lead to a reversal if broken.

Generated by AI

Community

Of the messages about PIRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	75%
Newcomers	—	—	—	25%

Regulars· Jun 21

AstraZeneca has discontinued the Phase 2a trial of Pieris Pharmaceuticals' asthma treatment, Elarekibep (PRS-060/AZD1402), due to new non-clinical safety findings from a 13-week toxicology study.
The discontinuation of the trial is a significant setback for Pieris Pharmaceuticals, which may need to reshuffle its partnerships and focus, and potentially even consider selling the company to return value to shareholders.
Pieris Pharmaceuticals' stock price has plummeted by 59.79% in the pre-market, with some investors considering the company "done" and others taking losses on small positions.

Newcomers· Jul 18

Pieris Pharmaceuticals is adjusting its strategy after AstraZeneca's discontinuation of enrollment and termination of their collaboration agreement.
The company is restructuring, reducing its workforce by approximately 70% as part of its cash preservation plan.
Pieris Pharmaceuticals' stock is experiencing a significant increase in price, up 20.25% as of the latest update, amidst the corporate restructuring and potential partnership opportunities.

Generated by AI

Palvella Therapeutics

Social

Jul 25

Sentiment

Bullish· Jul 24

Bearish· Jul 24

Topics

Analysts· Mar 19

Announcements· Aug 17

Technical Analysis· Jun 25

Community

Regulars· Jun 21

Newcomers· Jul 18

Also Discussed

Palvella Therapeutics Inc

Company Information

Location

Also Discussed

Social

Jul 25

Sentiment

Bullish· Jul 24

Bearish· Jul 24

Topics

Analysts· Mar 19

Announcements· Aug 17

Technical Analysis· Jun 25

Community

Regulars· Jun 21

Newcomers· Jul 18